Patents Assigned to Inventiva
  • Crystal form of Lanifibranor, preparation method therefor, and use thereof
    Patent number: 12686678
    Abstract: Provided are novel crystalline forms of Lanifibranor (Referred to as “Compound I”) and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing pan-PPAR agonists drugs and drugs for treating NASH. Compared with prior arts, the provided crystalline forms of Compound I have one or more improved properties, which solve the problems of the prior art and is of great value to the optimization and development of the drugs.
    Type: Grant
    Filed: November 24, 2023
    Date of Patent: July 21, 2026
    Assignee: INVENTIVA
    Inventors: Minhua Chen, Hongyan Zhu
  • METHOD OF MAKING LANIFIBRANOR
    Publication number: 20260193246
    Abstract: The present disclosure relates to a process for manufacturing lanifibranor which comprises reacting N-(4-chloro-2-iodo-phenyl)-1,3-benzothiazole-6-sulfonamide with 5-hexynoic acid in the presence of a Palladium catalyst and a copper salt.
    Type: Application
    Filed: March 4, 2026
    Publication date: July 9, 2026
    Applicant: INVENTIVA
    Inventors: Frederic BELL, Cécile BROSSEAU, Viktoriia ZUBAR
  • Methods and monitoring of treatment with lanifibranor
    Publication number: 20250290937
    Abstract: The present disclosure relates to methods for identifying a subject as eligible for treatment with lanifibranor, methods for treating a subject suffering from liver disease comprising administering lanifibranor to said subject and monitoring a subject's risk of experiencing a side effect caused by lanifibranor treatment.
    Type: Application
    Filed: March 14, 2025
    Publication date: September 18, 2025
    Applicant: INVENTIVA
    Inventors: Louis H. GRIFFEL, Martine BAUDIN
  • Deuterated derivatives of lanifibranor
    Patent number: 12291526
    Abstract: The present invention relates to deuterated derivatives of lanifibranor, in particular for use in therapy, specifically in the treatment of fibrotic diseases.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: May 6, 2025
    Assignee: INVENTIVA
    Inventors: Christian Montalbetti, Benaissa Boubia
  • NON-INVASIVE MONITORING OF LIVER DISEASE TREATMENT
    Publication number: 20240408069
    Abstract: The present disclosure relates to a method for assessing the effectiveness of a treatment with lanifibranor in a patient with a liver disease, the method comprising: a) in vitro measuring levels of a combination of biomarkers consisting of adiponectin, ferritin, MMP9 and transferrin in a biological sample from the patient; and b) assessing the effectiveness of the treatment with lanifibranor as a function of the levels measured in step a).
    Type: Application
    Filed: June 6, 2024
    Publication date: December 12, 2024
    Applicant: INVENTIVA
    Inventors: Pierre BROQUA, Philippe HUOT-MARCHAND, Lucile DZEN, Jérôme BOURSIER, Marine ROUX, Hugo HERVÉ
  • NON-INVASIVE MONITORING OF LIVER DISEASE TREATMENT
    Publication number: 20240410904
    Abstract: The present disclosure relates to a method of assessing the effectiveness of a treatment with lanifibranor in a patient with a liver disease, the method comprising: a) in vitro measuring levels of a combination of biomarkers consisting of CK18M65, hyaluronic acid, fructosamine and ALT in a biological sample from the patient; b) assessing the effectiveness of the treatment with lanifibranor as a function of the levels measured in step a).
    Type: Application
    Filed: June 6, 2024
    Publication date: December 12, 2024
    Applicant: INVENTIVA
    Inventors: Pierre BROQUA, Philippe HUOT-MARCHAND, Lucile DZEN, Jérôme BOURSIER, Marine ROUX, Hugo HERVÉ
  • Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer
    Patent number: 11999758
    Abstract: The invention relates to compounds of formula (I): wherein R1, R2, R3, R4, R5 and are as defined in the description.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: June 4, 2024
    Assignee: INVENTIVA
    Inventors: Martine Barth, Sylvie Contal, Jean-Louis Junien, Christine Massardier, Christian Montalbetti, Anne Soude
  • Method of treatment of cirrhosis
    Patent number: 11504380
    Abstract: The invention relates to a method of treating cirrhosis which comprises administering to a subject in need thereof lanifibranor or a deuterated derivative thereof.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: November 22, 2022
    Assignee: INVENTIVA
    Inventors: Guillaume Wettstein, Pierre Broqua, Jean-Louis Junien
  • Compounds as inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma
    Patent number: 10414739
    Abstract: The invention relates to compounds of formula (I): wherein R1, R2, R3, R4, R5 and R6 are as defined in the description. The compounds of formula (I) are inhibitors of the YAP/TAZ-TEAD interaction.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: September 17, 2019
    Assignee: INVENTIVA
    Inventors: Martine Barth, Sylvie Contal, Christian Montalbetti, Luc Spitzer
  • PPAR compounds for use in the treatment of fibrotic diseases
    Patent number: 10383858
    Abstract: The invention relates to the use of a pan-PPAR agonist, or of a pharmaceutical composition containing said agonist, for the treatment of a fibrotic condition.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: August 20, 2019
    Assignee: INVENTIVA
    Inventors: Irena Konstantinova, Jean-Michel Luccarini, Jean-Louis Junien, Pierre Broqua
  • Method of treatment of a mucopolysaccharidosis
    Patent number: 10092540
    Abstract: The present invention relates to the use of 4-methyl-2-oxo-2H-1-benzopyran-7-yl-5-thio-?-D-xylopyranoside in the treatment of a mucopolysaccharidosis such as type I mucopolysaccharidosis.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: October 9, 2018
    Assignee: INVENTIVA
    Inventors: Philippe Masson, Jean-Louis Junien, Mireille Tallandier
  • PPAR compounds for use in the treatment of fibrotic diseases
    Patent number: 10052311
    Abstract: The invention relates to the use of a pan-PPAR agonist, or of a pharmaceutical composition containing said agonist, for the treatment of a fibrotic condition.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: August 21, 2018
    Assignee: INVENTIVA
    Inventors: Irena Konstantinova, Jean-Michel Luccarini, Jean-Louis Junien, Pierre Broqua
  • Use of Odiparcil in the treatment of a mucopolysaccharidosis
    Patent number: 9561246
    Abstract: The present invention relates to a method of treatment of a mucopolysaccharidosis with 4-methyl-2-oxo-2H-1-benzopyran-7-yl-5-thio-?-D-xylopyranoside.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: February 7, 2017
    Assignee: Inventiva
    Inventors: Philippe Masson, Jean-Louis Junien